Lung Cancer Initiative of North Carolina Names Chris Rallis and Jim Sheegog to Board

Press Release Lung Cancer Initiative of North Carolina
FOR IMMEDIATE RELEASE ON September 6, 2017

Contact: Megan Snowdowne
Marketing & Communications Manager
Lung Cancer Initiative of North Carolina
(919) 784-0410 ext. 102
msnowdowne@lungcancerinitiativenc.org


Lung Cancer Initiative of North Carolina Names Chris Rallis and Jim Sheegog to Board

September 6, 2017 RALEIGH, N.C. - The Lung Cancer Initiative of North Carolina, the state’s leading nonprofit organization supporting lung cancer research and education, is proud to welcome Chris Rallis and Jim  Sheegog to serve on the board of directors.

“Chris and Jim bring highly accomplished professional backgrounds, strong business acumen, and demonstrated leadership capabilities to our team. We are thrilled to have them working as part of the Lung Cancer Initiative to provide important guidance toward our strategic efforts supporting lung cancer access, education and research,” says Amy Cipau, President and Founder of the Lung Cancer Initiative of North Carolina.

Chris has over 30 years’ of experience in the life science industry. He has worked within the areas of legal, business development, strategic planning and general management. He served in various of these capacities at Burroughs Welcome Co., and additionally was the President and Chief Operating Officer of Triangle Pharmaceuticals, Inc. Since 2008, Chris has been the Executive-in-Residence at Pappas Capital, a life science venture capital firm based in Durham, NC.

Jim has more than 28 years’ of corporate development experience consulting with world-class corporations and is the founder of Rowhill Consulting Group.  Prior to founding his consulting group, Jim worked in the pharma industry for 11 years.  He was also the Assistant Dean of Global Executive MBA program at Duke University, assisting with the creation of the first internet-based global MBA degree program.  Some of his best-known global clients have included Siemens, A.G., IBM, GlaxoSmithKline, Ford Motor Company, and Quintiles Transnational.

About The Lung Cancer Initiative of North Carolina

The Lung Cancer Initiative of North Carolina specializes in connecting patients, survivors and loved ones with the medical and research community. The mission is to decrease deaths and provide support to those affected by lung cancer through research, awareness, education and access programs across North Carolina.

www.LungCancerInitiativeNC.org

 

# # #

 


Category Tag(s): For the Media Press Releases

Comments

Leave a Reply

(0 / 500)

GuideStar Gold Participant